

Commercial/Healthcare Exchange PA Criteria *Effective: October 2012*

Prior Authorization: Psoriasis Topicals

Products Affected: Dovonex Cream/Foam (calcipotriene 0.005%); Duobrii Lotion (balobetasol and tazarotene 0.01%/0.045%); Enstilar Foam (calcipotriene/betamethasone dipropionate); Sorilux Foam (calcipotriene 0.005%)

Disease Description:

Psoriasis is a chronic skin condition that causes raised, red or silvery, scaly patches (plaques) to appear on the skin. It is an auto-immune disease in which patients shed their skin too quickly, causing dead skin cells to pile up on the surface. Normal skin cell turnover usually takes about a month, but for psoriasis patients the turnover can happen in only a few days. Affecting over 7 million adults in the United States, psoriasis is a common skin condition that develops in both men and women at equal rates – often first appearing between the ages of 15 and 35.

While scientists differ on its exact cause, genetics and the immune system both play major roles in the development of plaque psoriasis. Plaque psoriasis is the most common and can appear as red bumpy patches that are covered with a silver-white buildup of dead skin cells. It usually appears on the scalp, knees, and lower back and can be itchy and painful and may crack and bleed. According to the National Psoriasis Foundation, the goal is to get the patient's psoriasis down to 1 percent body surface area (BSA) or less three months after starting a new treatment. Topical treatments are often the first-line treatment recommended.

Covered Uses:

Duobrii Lotion, Enstilar Foam, Sorilux Foam, and Dovonex Cream are indicated treatment of plaque psoriasis in patients 18 years and older.

Dovonex Solution is indicated for the topical treatment of chronic, moderately severe psoriasis of the scalp.

Exclusion Criteria:

Duobrii Lotion

1. Patients who are pregnant.

Required Medical Information:

1. Diagnosis
2. Previous therapy regimen

Age Restrictions: 18 years of age and older

Prescriber Restrictions: Prescribed by, or in consultation with a dermatologist.

Coverage Duration:

Dovonex and Sorilux: no more than 8 weeks

Duobrii and Enstilar: 12 weeks only

Other Criteria:

Dovonex Cream or Sorilux Foam is medically necessary when all of the following criteria are met:



1. Patient has clinically documented plaque psoriasis; AND
2. Patient has a documented intolerance to, or treatment failure of an adequate trial of calcipotriene solution, ointment or cream.

Dovonex Solution is medically necessary when all of the following criteria are met:

1. Patient has clinically documented plaque psoriasis of the scalp; AND
2. Patient has a documented intolerance to, or treatment failure of an adequate trial of calcipotriene solution, ointment or cream.

Duobrii Lotion is medically necessary when all of the following criteria are met:

1. Patient has clinically documented plaque psoriasis; **AND**
2. Patient has a documented intolerance to, or treatment failure of an adequate trial of generic halobetasol cream or ointment in combination with generic tazarotene cream.

Enstilar Foam is medically necessary when the following criteria are met:

1. Patient is diagnosed with plaque psoriasis; AND
2. Patient has had an adequate trial (of 2 weeks' duration) of any one of the following:
 - a. Taclonex Suspension/Ointment (calcipotriene/betamethasone); OR
 - b. Dovonex Cream (calcipotriene cream); OR
 - c. Calcipotriene ointment; OR
 - d. Calcipotriene Solution; OR
 - e. Sorilux Foam

References:

1. Sorilux® foam full prescribing information. Stiefel Laboratories, Research Triangle Park, NC.
2. Dovonex package insert, LEO Laboratories, LTD, Dublin, Ireland
3. Enstilar package insert, LEO Pharma, 1 SylvanWay, Parsippany, NJ 07054
4. Duobrii [package insert]. Bridgewater, NJ; Bausch Health Americas, Inc.; April 2019.

Policy Revision history

Rev #	Type of Change	Summary of Change	Sections Affected	Date
1	Update	Added Duobrii Lotion	All	08/02/19
2	Update	Updated template from CCI to EH; CCI P&T Review History: 10/12, 10/13, 10/14, 11/15, 5/16, 8/17, 7/18 CCI Revision Record: 4/13, 8/16	All	8/02/2019

08/02/19